AIM ImmunoTech Files 8-K with Financials
Ticker: AIM · Form: 8-K · Filed: Oct 20, 2025 · CIK: 946644
Sentiment: neutral
Topics: financials, disclosure
TL;DR
AIM ImmunoTech dropped an 8-K with financials and Reg FD update. Check it out.
AI Summary
AIM ImmunoTech Inc. filed an 8-K on October 20, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Hemispherx Biopharma Inc., is based in Ocala, Florida, and operates in the Biological Products sector.
Why It Matters
This filing provides updated financial information and regulatory disclosures for AIM ImmunoTech Inc., which is crucial for investors to assess the company's current financial health and compliance status.
Risk Assessment
Risk Level: low — This is a routine filing of financial statements and disclosures, not indicating any immediate operational or financial distress.
Key Players & Entities
- AIM ImmunoTech Inc. (company) — Registrant
- Hemispherx Biopharma Inc. (company) — Former company name
- October 20, 2025 (date) — Date of report
- Ocala, FL (location) — Principal executive offices
- 001-27072 (other) — SEC File Number
FAQ
What specific type of Regulation FD Disclosure is being made by AIM ImmunoTech Inc. in this 8-K filing?
The filing indicates a 'Regulation FD Disclosure' as an item of information, but the specific details of the disclosure are not provided in the excerpt.
When was AIM ImmunoTech Inc. formerly known as Hemispherx Biopharma Inc.?
The date of the name change from Hemispherx Biopharma Inc. to AIM ImmunoTech Inc. was June 14, 1995.
What is the primary business sector for AIM ImmunoTech Inc.?
AIM ImmunoTech Inc. is classified under 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' with the SIC code 2836.
Where are AIM ImmunoTech Inc.'s principal executive offices located?
The principal executive offices of AIM ImmunoTech Inc. are located at 2117 SW Highway 484, Ocala, FL 34473.
What is the SEC File Number for AIM ImmunoTech Inc.?
The SEC File Number for AIM ImmunoTech Inc. is 001-27072.
Filing Stats: 934 words · 4 min read · ~3 pages · Grade level 11.8 · Accepted 2025-10-20 09:16:03
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share AIM NYSE American Item
Filing Documents
- form8-k.htm (8-K) — 42KB
- ex99-1.htm (EX-99.1) — 18KB
- ex99-1_001.jpg (GRAPHIC) — 453KB
- ex99-1_002.jpg (GRAPHIC) — 599KB
- ex99-1_003.jpg (GRAPHIC) — 346KB
- ex99-1_004.jpg (GRAPHIC) — 250KB
- ex99-1_005.jpg (GRAPHIC) — 458KB
- ex99-1_006.jpg (GRAPHIC) — 412KB
- ex99-1_007.jpg (GRAPHIC) — 297KB
- ex99-1_008.jpg (GRAPHIC) — 281KB
- ex99-1_009.jpg (GRAPHIC) — 229KB
- ex99-1_010.jpg (GRAPHIC) — 359KB
- ex99-1_011.jpg (GRAPHIC) — 296KB
- ex99-1_012.jpg (GRAPHIC) — 310KB
- ex99-1_013.jpg (GRAPHIC) — 213KB
- ex99-1_014.jpg (GRAPHIC) — 457KB
- ex99-1_015.jpg (GRAPHIC) — 331KB
- ex99-1_016.jpg (GRAPHIC) — 150KB
- ex99-1_017.jpg (GRAPHIC) — 372KB
- ex99-1_018.jpg (GRAPHIC) — 301KB
- ex99-1_019.jpg (GRAPHIC) — 209KB
- ex99-1_020.jpg (GRAPHIC) — 311KB
- 0001493152-25-018583.txt ( ) — 9361KB
- aim-20251020.xsd (EX-101.SCH) — 3KB
- aim-20251020_lab.xml (EX-101.LAB) — 33KB
- aim-20251020_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AIM ImmunoTech Inc. Date: October 20, 2025 By /s/ Thomas K. Equels Thomas K. Equels, CEO